<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Document</title>
    <!-- Font Awesome -->
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.9.0/css/all.min.css"
        integrity="sha512-q3eWabyZPc1XTCmF+8/LuE1ozpg5xxn7iO89yfSOd5/oKvyqLngoNGsx8jq92Y8eXJ/IRxQbEC+FGSYxtk2oiw=="
        crossorigin="anonymous" referrerpolicy="no-referrer" />
    <!-- Bootstrap CSS -->
    <link rel="stylesheet" href="css/bootstrap.min.css">
    <!-- Custom CSS -->
    <link rel="stylesheet" href="css/style.css">
</head>

<body>

    <div class="main_page5 fixedHeight">
        <div class="nav_orange">
            <div class="nav_orange_left">
                <h4 class="GothamBook mb-0">TOURMALINE-MM1 (MM1) study design: global phase 3 study investigating an
                    all-oral, PI-based regimen in 722 patients with relapsed and/or refractory multiple myeloma (RRMM)<sup class="GothamLight">1,2</sup>
                </h4>
            </div>
            <div class="nav_orange_right">
                <img src="img/logo_orange.png" alt="">
            </div>
        </div>
        <!-- page 5 middle box -->
            <div class="page5_middle_box" style="margin-top: 35px;">
                <div class="page5_box_1">
                    <p class="mb-0 text-center GothamBook">Patients with<br>RRMM who<br>received 1–3<br>prior therapies<br>(N=722)</p>
                </div>
                <div class="page5_box_2">
                    <div class="page5_box_2_child mb-4">
                        <p class="mb-0 text-center GothamBook">1 vs 2 or 3 <br> prior therapies</p>
                    </div>
                    <div class="page5_box_2_child mb-4">
                        <p class="mb-0 text-center GothamBook">PI exposed <br> vs PI naïve</p>
                    </div>
                    <div class="page5_box_2_child">
                        <p class="mb-0 text-center GothamBook">ISS stage I <br> or II vs III</p>
                    </div>
                </div>
                <div class="page5_box_3">
                    <p class="mb-0 text-center GothamBook">Double-blind 1:1 randomization</p>
                </div>
                <div class="page5_box_4">
                    <div class="page5_box_4_top">
                        <p class="page5_box_4_p_white w-100 pt-1 mb-2 GothamMedium text-center">(n=360)</p>
                        <div>
                            <div>
                                <p class="mb-2 GothamMedium text-center mt-2">Ixazomib (NINLARO)</p>
                                <img src="img/capsule.svg" alt="">
                                <p class="mb-0 mt-2 GothamMedium text-center">4 mg</p>
                                <p class="mb-0 text-center GothamLight">DAYS 1, 8, AND 15</p>
                            </div>
                            <div>
                                <p class="mb-2 GothamMedium text-center mt-2">Lenalidomide</p>
                                <img src="img/capsule.svg" alt="">
                                <p class="mb-0 mt-2 GothamMedium text-center">25 mg</p>
                                <p class="mb-0 text-center GothamLight">DAYS 1–21</p>
                            </div>
                            <div>
                                <p class="mb-2 GothamMedium text-center mt-2">Dexamethasone</p>
                                <img src="img/round_capsule.svg" alt="">
                                <p class="mb-0 mt-2 GothamMedium text-center">40 mg</p>
                                <p class="mb-0 text-center GothamLight">DAYS 1, 8, 15, AND 22</p>
                            </div>
                        </div>
                    </div>
                    <p class="page5_box_4_p_orange GothamBold w-100 mt-1 lh-sm mb-0 mt-2 text-center">REPEAT EVERY 28 DAYS</p>
                    <p class="page5_box_4_p_orange GothamLight dark_secondary w-100 mt-0 text-center">Until disease progression or unacceptable toxicity</p>
                    <div class="page5_box_4_bottom">
                        <p class="page5_box_4_p_white w-100 pt-1 mb-2 GothamMedium text-center dark_secondary">(n=362)</p>
                        <div>
                            <div style="color: #5c5c61 !important;">
                                <p class="mb-2 GothamMedium text-center mt-2 dark_secondary">Placebo</p>
                                <img src="img/capsule_silver.svg" alt="">
                                <p class="mb-0 mt-2 GothamMedium text-center dark_secondary">4 mg</p>
                                <p class="mb-0 text-center GothamLight dark_secondary">DAYS 1, 8, AND 15</p>
                            </div>
                            <div>
                                <p class="mb-2 GothamMedium text-center mt-2 dark_secondary">Lenalidomide</p>
                                <img src="img/capsule_silver.svg" alt="">
                                <p class="mb-0 mt-2 GothamMedium text-center dark_secondary">25 mg</p>
                                <p class="mb-0 text-center GothamLight dark_secondary">DAYS 1–21</p>
                            </div>
                            <div>
                                <p class="mb-2 GothamMedium text-center mt-2 dark_secondary">Dexamethasone</p>
                                <img src="img/round_capsule_silver.svg" alt="">
                                <p class="mb-0 mt-2 GothamMedium text-center dark_secondary">40 mg</p>
                                <p class="mb-0 text-center GothamLight dark_secondary">DAYS 1, 8, 15, AND 22</p>
                            </div>
                        </div>
                    </div>
                </div>
                <div class="page5_box_5">
                    <div class="page5_box5_child1" style="margin-bottom: 18px;">
                        <p class="GothamBold mb-1 fs-11 txt_blue">Primary endpoint:</p>
                        <p class="mb-0 GothamLight d-flex fs-11 align-items-start"><img class="mt-2 me-2" src="img/li_1.svg" alt=""> <span>Progression-free survival (PFS)</span></p>
                    </div>
                    <div class="page5_box5_child2">
                        <div>
                            <p class="GothamBold mb-1 txt_orange fs-11" >Secondary endpoints included:</p>
                            <p class="mb-0 GothamLight d-flex fs-11 align-items-start dark_secondary"><img class="mt-2 me-2" src="img/li_2.svg" alt=""> <span>Overall response rate (ORR)</span></p>
                        </div>
                        <div>
                            <p class="mb-0 GothamLight fs-11 d-flex align-items-start"><img class="mt-2 me-2" src="img/li_2.svg" alt=""> <span>Overall survival (OS) and PFS in patients with high-risk cytogenetics*</span></p>
                        </div>
                    </div>
                </div>
            </div>
        <!--  -->
            <div class="page5_middle_box pt-3 mb-3 mt-4">
                <div class="page5_btns_sm">
                    <a href="../page21/index.html" class="text-uppercase"><p class="mb-0 position-relative">ITT PFS</p></a>
                    <a href="../page23/index.html" class="text-uppercase"><p class="mb-0 position-relative">HIGH-RISK PFS</p></a>
                    <a href="../page28/index.html" class="text-uppercase"><p class="mb-0 position-relative">PRE-TREATED PFS</p></a>
                    <a href="../page25/index.html" class="text-uppercase"><p class="mb-0 position-relative">RESPONSE RATE</p></a>
                    <a href="../page31/index.html" class="text-uppercase"><p class="mb-0 position-relative">SAFETY</p></a>
                </div>
            </div>

            <div class="page5_middle_box page5_p_sm mb-2">
                <p class="GothamLight">
                    *Defined as patients with del(17p), t(4;14), or t(14;16). <br>
ISS = International Staging System; MM = multiple myeloma; ORR = overall response rate; OS = overall survival; PFS = progression-free survival; <br>
PI = proteasome inhibitor; RRMM = relapsed/refractory multiple myeloma.
                </p>
            </div>


            <div class="footer_page5 pb-4" style="margin-top: 11px;">
                <div class="d-flex align-items-end">
                    <div class="page5_btns_md">
                        <a href="../page5/index.html"><p class="mb-0 position-relative">MM1 study design</p></a>
                        <a href="../page6/index.html"><p class="mb-0 position-relative">MM1 patient baseline characteristics</p></a>
                        <a href="../page8/index.html"><p class="mb-0 position-relative">RWE study Hajek et al.</p></a>
                        <a href="../page15/index.html"><p class="mb-0 position-relative">RWE study Terpos et al.</p></a>
                        <a href="../page11/index.html"><p class="mb-0 position-relative">RWE study Chari et al.</p></a>
                        <a href="../page18/index.html"><p class="mb-0 position-relative">RWE study Minarik et al.</p></a>
                        <a href="../page21/index.html"><p class="mb-0 position-relative">MM1 PFS</p></a>
                        <a href="../page23/index.html"><p class="mb-0 position-relative">MM1 PFS in patients with high-risk cytogenetics</p></a>
                        <a href="../page25/index.html"><p class="mb-0 position-relative">MM1 response rate</p></a>
                        <a href="../page28/index.html"><p class="mb-0 position-relative">MM1 PFS in <br> pre-treated patients</p></a>
                        <a href="../page31/index.html"><p class="mb-0 position-relative">MM1 safety data</p></a>
                        <a href="../page34/index.html"><p class="mb-0 position-relative">Dosing</p></a>
                        <a href="../page36/index.html"><p class="mb-0 position-relative">Summary</p></a>
                        <a href="../page38/index.html"><p class="mb-0 position-relative">MM6 data</p></a>
                        <a></a>
                    </div>
                    <div class="footer_inner_nav1 position-static ms-auto bg-transparent p-0">
                        <ul>
                            <li>
                                <a href="../page4/index.html"><img src="img/page_1_footer_icon_1.svg" alt=""></a>
                            </li>
                            <li>
                                <a href="https://onetakeda.app.box.com/s/reg7tviee8telgupc6cccshjet2wqqqh" class="text-uppercase">pi</a>
                            </li>
                            <li>
                                <a href="../page7/index.html" class="text-uppercase">ref</a>
                            </li>
                        </ul>
                    </div>
                </div>
            </div>
    </div>

</body>

</html>